** Shares of Emergent BioSolutions EBS.N fall 12.5% to $5.98 in extended trading, the lowest since September
** Company reported a decline in its fourth-quarter revenue, which stood at $194.7 million, down from $276.6 million a year ago
** On an adjusted basis, company reported EPS of 5 cents, vs a loss of 77 cents previous year
** Company is moving forward with turnaround activities, a critical phase in its multi-year transformation plan - EBS
** Company's shares up 298.3% in 2024
(Reporting by Kritika Lamba in Bengaluru)
((Kritika.Lamba@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。